Venlafaxine Hydrochloride
Product Images NDC 50090-5929

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 50090-5929). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (310c558f 5135 4ddd B0bd F993c0ea8d62 01)

Venlafaxine Hydrochloride Extended-release Capsules, Usp (310c558f 5135 4ddd B0bd F993c0ea8d62 01)
The text provides a list of drugs that interact with Ethanol in individuals who have CYP2D6 enzyme extensive metabolizer and poor metabolizer phenotype. Ketoconazole, diazepam, and cimetidine are some of the drugs that interact with Ethanol in extensive metabolizers, while indinavir, metoprolol, imipramine, and lithium interact with Ethanol in poor metabolizers. The text also contains information on venlafaxine's analytical properties and PK fold change recommendations based on Cmax and AUC values. There are recommendations for dose adjustment and use with caution, especially in patients with hypertension, elderly or hepatic dysfunction, and monitoring of blood pressure.*
FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (310c558f 5135 4ddd B0bd F993c0ea8d62 02)

Venlafaxine Hydrochloride Extended-release Capsules, Usp (310c558f 5135 4ddd B0bd F993c0ea8d62 02)
This is a list of drugs and their interaction with other drugs. The list includes drugs such as Diazepam, Alprazolam, Indinavir, Metoprolol, Risperidone, Imipramine, Haloperidol, Caffeine, and Lithium. The table also shows the Analyte PKFold Change and 90% CRecommendation. The Cmax value is provided for different drugs indicating the level of dose adjustment or restriction to be followed while taking them. However, some of the information is not available due to errors.*
FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (310c558f 5135 4ddd B0bd F993c0ea8d62 03)

Venlafaxine Hydrochloride Extended-release Capsules, Usp (310c558f 5135 4ddd B0bd F993c0ea8d62 03)
This is a drug dosage recommendation guide for individuals with different health conditions, such as hepatic impairment, renal impairment, age, gender, and CYP2D8 polymorphism, for the drug analyte venlafaxine. The guide recommends reducing the dose by 50% or greater for individuals with hepatic impairment and increasing individualized dosing for other conditions such as mild/moderate impairment (renal), age (> 80 years), and CYP2D8 polymorphism, wherein no dose adjustment is recommended for others. The guide also provides fold change and 90% confidence intervals in the PK (pharmacokinetics) of the drug.*
FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (310c558f 5135 4ddd B0bd F993c0ea8d62 04)

Venlafaxine Hydrochloride Extended-release Capsules, Usp (310c558f 5135 4ddd B0bd F993c0ea8d62 04)
The text contains two different parts that are not related to each other. The first part includes the text "eHCI" and "H4C0 C" which are not identifiable words and might be a code or abbreviation of some sort. The second part indicates the name of a medication which is "venlafaxine hydrochloride."*
FDA Label Image

Label Image (Lbl500905929)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.